Similar articles

• Systemic treatments for eczema: a network meta-analysis.

  Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Sawangjit R, et al. Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206. doi: 10.1002/14651858.CD013206.pub2. Cochrane Database Syst Rev. 2020. PMID: 32927498 Free PMC article.
• Leukocytoclastic Vasculitis With Eosinophilia in a Patient Receiving Dupilumab Therapy.

  Wandler AM, Joseph JM, Haas C. Wandler AM, et al. Cureus. 2025 May 16;17(5):e84252. doi: 10.7759/cureus.84252. eCollection 2025 May. Cureus. 2025. PMID: 40530217 Free PMC article.
• Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

  Akenroye A, Lassiter G, Jackson JW, Keet C, Segal J, Alexander GC, Hong H. Akenroye A, et al. J Allergy Clin Immunol. 2022 Nov;150(5):1097-1105.e12. doi: 10.1016/j.jaci.2022.05.024. Epub 2022 Jun 27. J Allergy Clin Immunol. 2022. PMID: 35772597 Free PMC article.
• Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.

  Asbell P, Akpek E, Chamberlain W, Chen Z, Lawless E, Van Spall M, Ozturk ZE, Shumel B. Asbell P, et al. Adv Ther. 2025 Jul;42(7):3285-3305. doi: 10.1007/s12325-025-03209-4. Epub 2025 May 19. Adv Ther. 2025. PMID: 40388089 Free PMC article.
• Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review.

  Lazzeroni M, Kemp P, Fokkens WJ, Reitsma S. Lazzeroni M, et al. Rhinology. 2025 Aug 1;63(4):386-396. doi: 10.4193/Rhin24.528. Rhinology. 2025. PMID: 40305840